Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Rating) Director Renee P. Tannenbaum bought 10,000 shares of Cardiff Oncology stock in a transaction on Thursday, September 15th. The shares were acquired at an average price of $1.72 per share, for a total transaction of $17,200.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $17,200. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.
Cardiff Oncology Stock Up 9.5 %
Cardiff Oncology stock opened at $1.73 on Tuesday. Cardiff Oncology, Inc. has a 12 month low of $1.13 and a 12 month high of $7.63. The stock’s 50 day moving average is $2.51 and its 200-day moving average is $2.13.
Cardiff Oncology (NASDAQ:CRDF – Get Rating) last posted its earnings results on Thursday, August 4th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.01. Cardiff Oncology had a negative return on equity of 28.82% and a negative net margin of 9,841.41%. The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.08 million. Research analysts predict that Cardiff Oncology, Inc. will post -1.04 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Cardiff Oncology
Analysts Set New Price Targets
Several analysts recently issued reports on CRDF shares. Robert W. Baird dropped their target price on Cardiff Oncology from $9.00 to $6.00 and set an “outperform” rating on the stock in a report on Monday, August 29th. HC Wainwright dropped their target price on Cardiff Oncology from $22.00 to $14.00 and set a “buy” rating on the stock in a report on Friday. Finally, Piper Sandler lowered their price target on Cardiff Oncology from $7.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 13th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $9.75.
Cardiff Oncology Company Profile
Cardiff Oncology, Inc, a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
- Get a free copy of the StockNews.com research report on Cardiff Oncology (CRDF)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.